Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
7.11
+0.12 (1.72%)
Sep 4, 2025, 3:47 PM - Market open
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Astria Therapeutics stock have a consensus rating of "Buy" and an average price target of $32, which forecasts a 350.07% increase in the stock price over the next year. The lowest target is $16 and the highest is $47.
Price Target: $32 (+350.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Astria Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $25 → $26 | Buy | Maintains | $25 → $26 | +265.68% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +125.04% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +125.04% | Jun 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $47 | Buy | Reiterates | $47 | +561.04% | May 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $47 | Buy | Initiates | $47 | +561.04% | Apr 29, 2025 |
Financial Forecast
Revenue This Year
11.22M
Revenue Next Year
2.21M
from 11.22M
Decreased by -80.30%
EPS This Year
-2.17
from -1.68
EPS Next Year
-2.32
from -2.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 8.4M | |||
| Avg | 11.2M | 2.2M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | -25.1% | |||
| Avg | - | -80.3% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.94 | -1.73 | |||
| Avg | -2.17 | -2.32 | |||
| Low | -2.48 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.